DC drug price controls unconstitutional: court

9 January 2006

A US District Court judge has struck down a state law passed last year which would have enabled the District of Columbia to seek a compulsory license so that the city of Washington's Department of Health could give a patent to a generics maker, if the price of a drug sold to the city was deemed excessive (Marketletter May 16, 2005).

Ruling on a suit brought against the Prescription Drug Compulsory Manufacture License Act of 2005 by the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization, Judge Richard Leon said the law directly conflicted with incentives provided to drugmakers under federal patent law to develop innovative new products, and that it went against the will of Congress.

The law, which the DC Council passed unanimously last September, defined "excessive" prices as those 30% higher than in developed nations such as Australia, Canada, Germany and the UK. It would have required companies to prove the price was not excessive, citing R&D costs, profit margins, etc.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight